Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 136

1.

Clinical roundtable monograph. Current treatment options for metastatic breast cancer: what now?

Rugo HS, O'Shaughnessy JA, Perez EA.

Clin Adv Hematol Oncol. 2011 Nov;9(11):1-16.

PMID:
22355830
2.

Current treatment options for metastatic breast cancer: what now?

Rugo HS, O'Shaughnessy JA, Perez EA.

Clin Adv Hematol Oncol. 2011 Nov;9(11 Suppl 25):1-16.

PMID:
22362269
3.

Bevacizumab: a review of its use in combination with paclitaxel or capecitabine as first-line therapy for HER2-negative metastatic breast cancer.

Croom KF, Dhillon S.

Drugs. 2011 Nov 12;71(16):2213-29. doi: 10.2165/11207720-000000000-00000. Review.

PMID:
22035518
4.

Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial.

Lang I, Brodowicz T, Ryvo L, Kahan Z, Greil R, Beslija S, Stemmer SM, Kaufman B, Zvirbule Z, Steger GG, Melichar B, Pienkowski T, Sirbu D, Messinger D, Zielinski C; Central European Cooperative Oncology Group.

Lancet Oncol. 2013 Feb;14(2):125-33. doi: 10.1016/S1470-2045(12)70566-1. Epub 2013 Jan 10.

PMID:
23312888
5.

The role of angiogenesis inhibition in the treatment of breast cancer.

Sledge GW Jr, Rugo HS, Burstein HJ.

Clin Adv Hematol Oncol. 2006 Oct;4(10 Suppl 21):1-10; quiz 11-2. Review.

PMID:
17139244
6.

Bevacizumab in combination with a taxane for the first-line treatment of HER2-negative metastatic breast cancer.

Rodgers M, Soares M, Epstein D, Yang H, Fox D, Eastwood A.

Health Technol Assess. 2011 May;15 Suppl 1:1-12. doi: 10.3310/hta15suppl1/01. Review.

7.

Targeting angiogenesis in metastatic breast cancer.

Reddy S, Raffin M, Kaklamani V.

Oncologist. 2012;17(8):1014-26. doi: 10.1634/theoncologist.2012-0043. Epub 2012 Jul 27.

8.

Primary tumor location and bevacizumab effectiveness in patients with metastatic colorectal cancer.

Boisen MK, Johansen JS, Dehlendorff C, Larsen JS, Osterlind K, Hansen J, Nielsen SE, Pfeiffer P, Tarpgaard LS, Holländer NH, Keldsen N, Hansen TF, Jensen BB, Jensen BV.

Ann Oncol. 2013 Oct;24(10):2554-9. doi: 10.1093/annonc/mdt253. Epub 2013 Jul 17.

PMID:
23864097
9.

[Recent advances in targeted therapies in the treatment of HER2-positive metastatic breast cancer].

Ismaili N, Belbaraka R, Elomrani A, Khouchani M, Tahri A.

Presse Med. 2013 Nov;42(11):1461-8. doi: 10.1016/j.lpm.2013.01.066. Epub 2013 May 27. Review. French.

PMID:
23721860
10.

Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial.

Gligorov J, Doval D, Bines J, Alba E, Cortes P, Pierga JY, Gupta V, Costa R, Srock S, de Ducla S, Freudensprung U, Mustacchi G.

Lancet Oncol. 2014 Nov;15(12):1351-60. doi: 10.1016/S1470-2045(14)70444-9. Epub 2014 Sep 28.

PMID:
25273343
11.

Update on clinical data combining capecitabine with targeted agents in newly diagnosed colorectal cancer.

Lee JJ, Chu E.

Clin Colorectal Cancer. 2007 Dec;7 Suppl 1:S16-20. Review.

PMID:
18361802
12.

Current combination chemotherapy regimens for metastatic breast cancer.

Schwartz J.

Am J Health Syst Pharm. 2009 Dec 1;66(23 Suppl 6):S3-8. doi: 10.2146/ajhp090438. Review.

PMID:
19923317
13.

Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer.

Wagner AD, Thomssen C, Haerting J, Unverzagt S.

Cochrane Database Syst Rev. 2012 Jul 11;(7):CD008941. doi: 10.1002/14651858.CD008941.pub2. Review.

PMID:
22786517
14.

Combination versus sequential single-agent therapy in metastatic breast cancer.

Miles D, von Minckwitz G, Seidman AD.

Oncologist. 2002;7 Suppl 6:13-9. Review. Erratum in: Oncologist. 2003;8(1):127.

15.

Bevacizumab in metastatic breast cancer: a meta-analysis of randomized controlled trials.

Valachis A, Polyzos NP, Patsopoulos NA, Georgoulias V, Mavroudis D, Mauri D.

Breast Cancer Res Treat. 2010 Jul;122(1):1-7. doi: 10.1007/s10549-009-0727-0. Epub 2010 Jan 9. Review.

PMID:
20063120
16.

Lapatinib plus capecitabine for HER2-positive advanced breast cancer.

Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, Jagiello-Gruszfeld A, Crown J, Chan A, Kaufman B, Skarlos D, Campone M, Davidson N, Berger M, Oliva C, Rubin SD, Stein S, Cameron D.

N Engl J Med. 2006 Dec 28;355(26):2733-43. Erratum in: N Engl J Med. 2007 Apr 5;356(14):1487.

17.

[Efficacy and safety of regimens of capecitabine-based chemotherapy in the treatment of advanced breast cancer].

Huang HY, Jiang ZF, Wang T, Zhang SH, Bian L, Cao Y, Wu SK, Song ST.

Zhonghua Zhong Liu Za Zhi. 2011 Nov;33(11):850-3. Chinese.

PMID:
22335952
18.

Survival benefit with capecitabine/docetaxel versus docetaxel alone: analysis of therapy in a randomized phase III trial.

Miles D, Vukelja S, Moiseyenko V, Cervantes G, Mauriac L, Van Hazel G, Liu WY, Ayoub JP, O'Shaughnessy JA.

Clin Breast Cancer. 2004 Oct;5(4):273-8.

PMID:
15507172
19.

The efficacy of HER2-targeted agents in metastatic breast cancer: a meta-analysis.

Harris CA, Ward RL, Dobbins TA, Drew AK, Pearson S.

Ann Oncol. 2011 Jun;22(6):1308-17. doi: 10.1093/annonc/mdq593. Epub 2010 Nov 30.

PMID:
21119031
20.

Trastuzumab-containing regimens for metastatic breast cancer.

Balduzzi S, Mantarro S, Guarneri V, Tagliabue L, Pistotti V, Moja L, D'Amico R.

Cochrane Database Syst Rev. 2014 Jun 12;(6):CD006242. doi: 10.1002/14651858.CD006242.pub2. Review.

Supplemental Content

Support Center